Evidence map›Paper›PMID 41646474›Full record

ArticleESMO gastrointestinal oncology2025

Continuous imaging to evaluate growth and drug responses of patient-derived colorectal tumouroids.

B C Sakshaug, E Folkesson, T H Haukaas, M S Sigfúsdóttir, H H Trøen, S B Sperstad, H C H Bwanika, C Ringers, I A Bergstrøm, G Klinkenberg and 2 more

Erratum issuedAbstract read
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

B C SakshaugDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
E FolkessonDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
T H HaukaasDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim.
M S SigfúsdóttirDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim.
H H TrøenDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim.
S B SperstadDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim.
H C H BwanikaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
C RingersDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
I A BergstrømDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
G KlinkenbergDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim.
T VisnesDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim.
Å FlobakDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The use of patient-derived tumouroids is expected to have major implications in preclinical drug testing and clinical decision support. Data acquisition from these samples in drug screens, however, is often limited by time-consuming procedures, scarce screening material, and destructive, single-parameter endpoint measurements. Design: We seek to increase data collected from patient-derived tumouroids and here present a method for non-destructive, continuous image-based analysis of colorectal tumouroid growth and shape under chemotherapeutic perturbations, conducted within a clinically relevant timeframe. Results: We assessed several readouts automatically derived from continuous imaging data and concluded that tumouroid growth, and the effect of growth inhibiting drugs, can be robustly monitored by measuring the total tumouroid-covered area in images. We also found that measures of average tumouroid size, diameter, and perimeter provide complementary insights. Conclusions: Our tumouroid analysis method offers a strategy to maximise data extraction from non-destructive imaging techniques while preserving tumouroids for future research, all within a clinically relevant timeframe.

Indexed as

chemotherapycolorectal cancerimagingpatient-derived tumouroidspersonalised medicine

Identifiers

PMID41646474
PMCPMC12836542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.